ClinicalTrials.gg
CompletedNCT05707403Updated Nov 28, 2025Results posted

A Study in Healthy Men to Test How BI 1015550 is Taken up and Handled by the Body

A Phase 1 interventional study of BI 1015550 and BI 1015550 mixed with [C-14]-BI 1015550 in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Netherlands. Open to male participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-28.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
Male
01

Study summary

This trial is intended to examine the absolute oral bioavailability of BI 1015550 as tablet formulation for oral administration, using an intravenous microtracer approach with [14C]-labelled BI 1015550. These data are considered necessary to further support the understanding of the pharmacokinetics of BI 1015550.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male subjects according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs (blood pressure (BP), pulse rate (PR)), 12-lead (ECG), and clinical laboratory tests
  • Age of 18 to 65 years (inclusive)
  • (BMI) of 18.5 to 29.9 kg/m2 (inclusive)
  • Signed and dated written in accordance with International Council for Harmonisation-Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial

Exclusion criteria

Exclusion Criteria:

  • Any finding in the medical examination (including BP, PR or ) deviating from normal and assessed as by the investigator
  • Repeated measurement of systolic blood pressure outside the range of 90 to 140 millimetre(s) of mercury (mmHg), diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of 40 to 100 beats per minute (bpm)
  • Any laboratory value outside the reference range that the investigator considers to be of clinical relevance
  • Any evidence of a concomitant disease assessed as clinically relevant by the investigator
  • Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  • Cholecystectomy or other surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except appendectomy or simple hernia repair)
  • Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders (including but not limited to major depressive disorder or history of suicide attempts)
  • History of relevant orthostatic hypotension, fainting spells, or blackouts Further exclusion criteria apply.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    Test treatment (T) followed by Reference treatment (R)

    Drug: BI 1015550 · Drug: BI 1015550 mixed with [C-14]-BI 1015550

Interventions

  • Treatment T

    Also known as: Nerandomilast, JASCAYD®

  • DrugBI 1015550 mixed with [C-14]-BI 1015550

    Drug page: Nerandomilast

    Treatment R

    Also known as: Nerandomilast, JASCAYD®

06

What researchers measure

Primary outcomes

  1. Dose Normalized Area Under the Concentration-time Curve of BI 1015550 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-inf)

    Dose normalized AUC0-inf of \[14C\]-BI 1015550 after intravenous (i.v.) administration and AUC0-inf of BI 1015550 after oral (p.o.) administration are reported. The analysis was performed only on the pharmacologically active R-enantiomer.

    Time frame: Between waking up and still prior to drug intake and 0.5*, 0.75*, 1*, 1.5*, 1.58±, 1.67±, 1.75, 2, 2.5±, 3, 4, 5±, 6, 7±, 8, 12, 16, 24, 36, 48, 72, 120, 168, 216± hours after intake of oral BI 1015550 tablet, *for T treatment, ±only for R treatment.

Secondary outcomes

  1. Dose Normalized Maximum Measured Concentration of BI 1015550 in Plasma (Cmax)

    Dose normalized Cmax of BI 1015550 after oral administration and Cmax of \[14C\]-BI 1015550 after intravenous administration is reported. The analysis was performed only on the pharmacologically active R-enantiomer.

    Time frame: Between waking up and still prior to drug intake and 0.5*, 0.75*, 1*, 1.5*, 1.58±, 1.67±, 1.75, 2, 2.5±, 3, 4, 5±, 6, 7±, 8, 12, 16, 24, 36, 48, 72, 120, 168, 216± hours after intake of oral BI 1015550 tablet, *for T treatment, ±only for R treatment.

07

Results

Posted Nov 28, 2025

Participant flow

A non-randomised, open-label, single period, single arm trial to determine the absolute oral bioavailability of BI 1015550 in healthy male subjects.

Participant flow — Overall Study
Milestone18 mg BI 1015550 / 100 μg BI 1015550 (C-14)
Started8
Completed8
Not completed0

Outcome measures

PrimaryDose Normalized Area Under the Concentration-time Curve of BI 1015550 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-inf)

Dose normalized AUC0-inf of \[14C\]-BI 1015550 after intravenous (i.v.) administration and AUC0-inf of BI 1015550 after oral (p.o.) administration are reported. The analysis was performed only on the pharmacologically active R-enantiomer.

Time frame:
Between waking up and still prior to drug intake and 0.5*, 0.75*, 1*, 1.5*, 1.58±, 1.67±, 1.75, 2, 2.5±, 3, 4, 5±, 6, 7±, 8, 12, 16, 24, 36, 48, 72, 120, 168, 216± hours after intake of oral BI 1015550 tablet, *for T treatment, ±only for R treatment.
Reported as:
Geometric mean · Hours*millimole/liter/kilogram
Dose Normalized Area Under the Concentration-time Curve of BI 1015550 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-inf)
Hours*millimole/liter/kilogramR-BI 1015550 18 mg tablet (T)14C-R-BI 1015550 10 μg i.v. (R)
Dose Normalized Area Under the Concentration-time Curve of BI 1015550 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-inf)118.27 ± 1.07161.69 ± 1.07
Statistical analysis
  • R-BI 1015550 18 mg tablet (T) vs 14C-R-BI 1015550 10 μg i.v. (R) · Ratio (t/r) [%]: 73.15 · 90% CI 67.32 to 79.48Ratio \[%\] is calculated as Test / Reference Intra-individual geometric Coefficient of Variation (gCV) = 8.8 %.
SecondaryDose Normalized Maximum Measured Concentration of BI 1015550 in Plasma (Cmax)

Dose normalized Cmax of BI 1015550 after oral administration and Cmax of \[14C\]-BI 1015550 after intravenous administration is reported. The analysis was performed only on the pharmacologically active R-enantiomer.

Time frame:
Between waking up and still prior to drug intake and 0.5*, 0.75*, 1*, 1.5*, 1.58±, 1.67±, 1.75, 2, 2.5±, 3, 4, 5±, 6, 7±, 8, 12, 16, 24, 36, 48, 72, 120, 168, 216± hours after intake of oral BI 1015550 tablet, *for T treatment, ±only for R treatment.
Reported as:
Geometric mean · Picomole/Liter/microgram
Dose Normalized Maximum Measured Concentration of BI 1015550 in Plasma (Cmax)
Picomole/Liter/microgramR-BI 1015550 18 mg tablet (T)14C-R-BI 1015550 10 μg i.v. (R)
Dose Normalized Maximum Measured Concentration of BI 1015550 in Plasma (Cmax)24.53 ± 1.1373.05 ± 1.13
Statistical analysis
  • R-BI 1015550 18 mg tablet (T) vs 14C-R-BI 1015550 10 μg i.v. (R) · Ratio (t/r) [%]: 33.58 · 90% CI 29.40 to 38.36Ratio \[%\] is calculated as Test / Reference Intra-individual geometric Coefficient of Variation (gCV) = 14.1 %

Adverse events

Collected over For all-cause mortality: From study start until end of study up to 22 days. For serious and other adverse events: From drug administration until the last dose, plus 7 days of residual effect period, up to 7 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
18 mg BI 1015550 / 100 μg BI 1015550 (C-14)0/8 (0%)0/8 (0%)0/8 (0%)

Baseline characteristics

Treated Set (TS): All subjects who were treated with at least one dose of trial drug.

Age, Continuous
Age, Continuous(Years)18 mg BI 1015550 / 100 μg BI 1015550 (C-14)
Mean28.9 ± 13.9
Sex: Female, Male
Sex: Female, Male(Participants)18 mg BI 1015550 / 100 μg BI 1015550 (C-14)
Female0
Male8
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)18 mg BI 1015550 / 100 μg BI 1015550 (C-14)
Hispanic or Latino0
Not Hispanic or Latino8
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)18 mg BI 1015550 / 100 μg BI 1015550 (C-14)
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American0
White6
More than one race1
Unknown or Not Reported0
08

Study locations

1 site
  • ICON
    Groningen, 9728 NZ, Netherlands
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.mystudywindow.com/msw/datatransparency

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2023 to primary completion in Mar 2023, 1 month.

Results were first posted in Nov 2025, 2 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2023
First posted
Jan 31, 2023
StartActual
Feb 14, 2023
Primary completionActual
Mar 28, 2023
CompletionActual
Mar 28, 2023
Results first posted
Nov 28, 2025
Last update
Nov 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05707403
Responsible party
Sponsor
First posted
Jan 31, 2023
Start date
Feb 14, 2023
Primary completion
Mar 28, 2023
Completion
Mar 28, 2023
Results posted
Nov 28, 2025
Last update
Nov 28, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nerandomilast

Start the discussion